20 compound-focused publications · 13 studies with detailed explanations.
Click a paper title or Read summary to open its reading page. Find a detailed explanation or a short, attributed abstract excerpt, then follow the original source for the full conclusion.
20 of 20 publications · Showing 1–20
Kraskovskaya N, Linkova N, Sakhenberg E et al. · International journal of molecular sciences
Why included: The neuronal-cell experiment directly tested EDR (Pinealon) alongside other short peptides.
Journal Article
Khavinson V, Linkova N, Kozhevnikova E et al. · Molecules (Basel, Switzerland)
Why included: The mechanistic review focuses on EDR (Pinealon) peptide interactions and gene-regulation hypotheses.
Journal Article · Review
Silanteva IA, Komolkin AV, Morozova EA et al. · The journal of physical chemistry. B
Why included: An experimental DNA-interaction study directly tested the Glu-Asp-Arg tripeptide (Pinealon).
Journal Article
Myakotnykh VS, Torgashov MN, Egorin KV et al. · Advances in gerontology = Uspekhi gerontologii
Why included: A human report examined combined Pinealon and Vesugen treatment; this does not isolate Pinealon effects.
Comparative Study · Journal Article
Mendzheritsky AM, Karantysh GV, Ryzhak GA et al. · Advances in gerontology = Uspekhi gerontologii
Why included: The compound is a named subject of the publication title.
Journal Article
Meshchaninov VN, Tkachenko EL, Zharkov SV et al. · Advances in gerontology = Uspekhi gerontologii
Why included: A clinical report studied Pinealon and Vesugen in people with multiple illnesses; combined treatments limit attribution.
English Abstract · Journal Article
Mendzheritskiĭ AM, Karantysh GV, Ryzhak GA et al. · Advances in gerontology = Uspekhi gerontologii
Why included: The compound is a named subject of the publication title.
Journal Article
Khavinson VKh, Lin'kova NS, Tarnovskaya SI et al. · Bulletin of experimental biology and medicine
Why included: Brain-cortex culture experiments tested the Glu-Asp-Arg tripeptide (Pinealon) and serotonin-related measures.
Journal Article
Mendzheritski AM, Karantysh GV, Abramchuk VA et al. · Advances in gerontology = Uspekhi gerontologii
Why included: The rat learning and caspase experiment directly tested Pinealon.
English Abstract · Journal Article
Fedoreyeva LI, Smirnova TA, Kolomijtseva GY et al. · Biochemistry. Biokhimiia
Why included: An in vitro binding experiment tested the Glu-Asp-Arg tripeptide with histones; it is not a human efficacy study.
Journal Article · Research Support, Non-U.S. Gov't
Bashkireva AS, Artamonova VG · Advances in gerontology = Uspekhi gerontologii
Why included: The worker study examined combined Pinealon and Vesugen for neurotic-disorder measures; attribution is limited.
Clinical Trial · English Abstract · Journal Article
Voicekhovskaya MA, Chalisova NI, Kontsevaya EA et al. · Bulletin of experimental biology and medicine
Why included: Rat skin-culture experiments tested T33, the Glu-Asp-Arg tripeptide.
Journal Article
Nazimko VA, Morgul' EV, Petrova OA et al. · Advances in gerontology = Uspekhi gerontologii
Why included: The locomotive-worker report studied adaptation measures after peptide treatment including Pinealon.
English Abstract · Journal Article
Arutjunyan A, Kozina L, Stvolinskiy S et al. · International journal of clinical and experimental medicine
Why included: The compound is a named subject of the publication title.
Journal Article
Khavinson VKh, Linkova NS, Chalisova NI et al. · Bulletin of experimental biology and medicine
Why included: Rat pineal-cell cultures tested Glu-Asp-Arg, including its lack of effect on apoptosis-inducing factor.
Journal Article
Fedoreyeva LI, Kireev II, Khavinson VKh et al. · Biochemistry. Biokhimiia
Why included: The study tested HeLa-cell uptake of fluorescently labeled Pinealon and separate in vitro peptide-DNA interactions.
Journal Article · Research Support, Non-U.S. Gov't
Khavinson V, Ribakova Y, Kulebiakin K et al. · Rejuvenation research
Why included: The compound is a named subject of the publication title.
Journal Article · Research Support, Non-U.S. Gov't
Mendzheritskiĭ AM, Karantysh GV, Ivonina KO · Advances in gerontology = Uspekhi gerontologii
Why included: Pinealon pretreatment was tested in an old-rat cerebral-ischemia and caspase experiment.
Comparative Study · Journal Article
Kozina LS, Arutiunian AV, Stvolinskiĭ SL et al. · Advances in gerontology = Uspekhi gerontologii
Why included: Cell and lipoprotein oxidation experiments directly tested Pinealon, including increased baseline reactive oxygen species.
English Abstract · Journal Article
Kozina LS · Advances in gerontology = Uspekhi gerontologii
Why included: Pinealon was tested in hypoxia experiments involving rats and neurons.
Journal Article
A combined preparation prevents isolation of Pinealon's contribution. Favorable scores and selected safety markers do not establish a lifespan benefit or general safety.
A combined regimen cannot isolate Pinealon's effect; surrogate indicators are not demonstrated extension of lifespan or healthy lifespan.
[Comparative analysis of different methods of geroprotective].
Myakotnykh VS et al. · Advances in gerontology = Uspekhi gerontologii · 2016
Why included: A human report examined combined Pinealon and Vesugen treatment; this does not isolate Pinealon effects.
Read the original study PMID 28539017 · PubMedOpen study summaryChanges in a biological-age score do not demonstrate longer life. The abstract reports potentially unfavorable marker changes and does not clearly establish a blinded randomized comparison; unchanged chromatin condensation is not comprehensive genetic safety evidence.
Small clinical biomarker reports do not establish rejuvenation or genetic safety. The reported marker changes include potentially unfavorable findings.
[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION].
Meshchaninov VN et al. · Advances in gerontology = Uspekhi gerontologii · 2015
Why included: A clinical report studied Pinealon and Vesugen in people with multiple illnesses; combined treatments limit attribution.
Read the original study PMID 26390612 · PubMedOpen study summaryResponses differed between peptides and stress models. These laboratory changes do not establish a geroprotective or cognitive effect in people.
Results were model- and peptide-dependent. These experimental markers do not establish human neuroprotection.
[Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia].
Mendzheritsky AM et al. · Advances in gerontology = Uspekhi gerontologii · 2015
Why included: The compound is a named subject of the publication title.
Read the original study PMID 28509493 · PubMedOpen study summaryThe authors interpreted these markers as possible neurogenesis and inflammation-related changes. Marker changes alone do not directly measure restored cognition or clinical neurological benefit.
Marker changes do not directly demonstrate formation of new functional neurons or clinical cognitive benefit.
[Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon].
Mendzheritskiĭ AM et al. · Advances in gerontology = Uspekhi gerontologii · 2014
Why included: The compound is a named subject of the publication title.
Read the original study PMID 25051764 · PubMedOpen study summaryLearning differences were reported in rats, while the link with caspase-3 remained an interpretation. The paper does not measure human memory or aging.
Maze performance in rats does not establish treatment of human cognitive impairment.
[Effect of peptide geroprotectors on the navigation system learning and caspase-3 in brain structures in rats of different age].
Mendzheritski AM et al. · Advances in gerontology = Uspekhi gerontologii · 2013
Why included: The rat learning and caspase experiment directly tested Pinealon.
Read the original study PMID 28976148 · PubMedOpen study summaryBehavioral observations and isolated-neuron measurements were reported in offspring exposed to a particular prenatal stress model. These findings do not describe cognition in healthy adult humans or show that a change in a cell-stress marker predicts a clinical benefit.
A specific prenatal rat model cannot establish cognitive benefits in healthy adults or clinical neurological outcomes.
Pinealon protects the rat offspring from prenatal hyperhomocysteinemia
Arutjunyan A et al. · International Journal of Clinical and Experimental Medicine · 2012
Why included: The compound is a named subject of the publication title.
Read the original study PMCID PMC3342713 · PubMed CentralOpen study summaryThe short occupational report does not clearly describe a randomized, blinded control in its abstract. Its scores are not measurements of lifespan or prevention of workplace accidents.
The abstract does not provide enough control or follow-up information to establish delayed aging or durable health benefits.
[Analysis of some parameters of biological age and adaptation possibilities of workers of locomotive brigades].
Nazimko VA et al. · Advances in gerontology = Uspekhi gerontologii · 2012
Why included: The locomotive-worker report studied adaptation measures after peptide treatment including Pinealon.
Read the original study PMID 22708445 · PubMedOpen study summaryThe occupational comparison and peptide observations are different parts of the report. Combined Pinealon/Vesugen findings and an incompletely described treatment comparison limit causal conclusions.
The screened population is not necessarily the intervention sample. Combined treatment and limited methodological detail prevent attribution to Pinealon alone.
[The peptide correction of neurotic disorders among professional truck-drivers].
Bashkireva AS et al. · Advances in gerontology = Uspekhi gerontologii · 2012
Why included: The worker study examined combined Pinealon and Vesugen for neurotic-disorder measures; attribution is limited.
Read the original study PMID 23734521 · PubMedOpen study summaryCell survival, oxidative-stress markers, and cell-cycle behavior are different outcomes. The reported changes help describe responses in these cultures, but are not measurements of memory, learning, or a neurological treatment effect in people.
Cell viability and signaling endpoints do not establish cognitive improvement, neurological treatment outcomes, or human safety.
Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes.
Khavinson V et al. · Rejuvenation research · 2011
Why included: The compound is a named subject of the publication title.
Read the original study PMID 21978084 · PubMedOpen study summaryThe reported behavior included reduced activity as well as other changes. Pretreatment and enzyme measurements do not establish cognitive improvement after stroke in people.
The original paper is in Russian, with an English abstract. Animal pretreatment findings and mixed behavioral effects do not establish clinical stroke recovery or cognitive benefit.
[Effects of introduction of short peptides before carotid artery occlusion on behaviour and caspase-3 activity in the brain of old rats].
Mendzheritskiĭ AM et al. · Advances in gerontology = Uspekhi gerontologii · 2011
Why included: Pinealon pretreatment was tested in an old-rat cerebral-ischemia and caspase experiment.
Read the original study PMID 21809624 · PubMedOpen study summaryThe binding and localization results suggest molecular interactions. They do not establish beneficial gene regulation, safety, or a neurological effect in people.
Fluorescently labeled peptides and a cancer-cell line do not establish human gene regulation, therapeutic epigenetic effects, or safety.
Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.
Fedoreyeva LI et al. · Biochemistry. Biokhimiia · 2011
Why included: The study tested HeLa-cell uptake of fluorescently labeled Pinealon and separate in vitro peptide-DNA interactions.
Read the original study PMID 22117547 · PubMedOpen study summaryThe authors proposed several contributing mechanisms rather than a simple direct antioxidant effect. The model does not establish prevention of human hypoxic brain injury.
Experimental stress protection does not establish human cognitive improvement or clinical neuroprotection.
[Investigation of antihypoxic properties of short peptides].
Kozina LS et al. · Advances in gerontology = Uspekhi gerontologii · 2008
Why included: Pinealon was tested in hypoxia experiments involving rats and neurons.
Read the original study PMID 18546825 · PubMedOpen study summaryThe peptides did not show direct antioxidant activity in these assays, and some reactive-oxygen measurements rose. Reduced cell death should not be simplified into a uniform antioxidant claim.
Different laboratory endpoints moved in different directions. These assays do not establish a uniformly antioxidant effect or a clinical benefit.
[Biological activity of regulatory peptides in model experiments in vitro].
Kozina LS et al. · Advances in gerontology = Uspekhi gerontologii · 2008
Why included: Cell and lipoprotein oxidation experiments directly tested Pinealon, including increased baseline reactive oxygen species.
Read the original study PMID 18546826 · PubMedOpen study summary